Orforglipron Matches Insulin Glargine on Heart Safety in Trial

Comparing an Oral Nonpeptide Pill to Injected Insulin

New trial results presented at the annual meeting of the European Association for the Study of Diabetes (EASD) evaluated whether a daily pill could replace daily injections. Researchers tested orforglipron against insulin glargine in adults with type 2 diabetes who faced elevated cardiovascular risk. The findings appeared simultaneously in The Lancet.

Orforglipron is an oral, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist. Regulators approved the medication for obesity in the United States in April 2026 and in the United Kingdom in August 2026. Prior to this study, researchers had not evaluated the cardiovascular safety of nonpeptide GLP-1 receptor agonists directly against injected insulin.

The trial enrolled 2,749 adults who had a baseline glycated hemoglobin (HbA1c) between 7.0% and 10.5% alongside a body mass index (BMI) of at least 25 kg/m2. Among all participants, 85.9% had established cardiovascular disease and 37.5% had chronic kidney disease (CKD). Participants were already taking up to three background blood sugar medications, including metformin, sulfonylureas, or a sodium-glucose cotransporter-2 inhibitor (SGLT2i).

• Participants were randomly assigned to open-label oral orforglipron once daily up to 36 mg or daily titrated insulin glargine injections.
• The primary endpoint tracked the time to a four-component major adverse cardiovascular event (MACE-4).
• Eli Lilly sponsored the multicenter clinical trial.

Cardiovascular Safety and Blood Sugar Outcomes

Orforglipron met the statistical threshold for cardiovascular non-inferiority compared to insulin glargine over a median follow-up of two years. A primary MACE-4 event occurred in 57 participants (4.2%) taking orforglipron and in 67 participants (5.0%) receiving insulin glargine. The hazard ratio was 16% lower in the orforglipron group, though that relative difference was not statistically significant.

The oral treatment produced greater improvements in glycemic control than the daily injections. Orforglipron showed both non-inferiority and statistical superiority for HbA1c reduction, with an estimated treatment difference of -0.50% (-5.5 mmol/mol) compared to insulin glargine. This benefit occurred in a study population with an average starting HbA1c of 8.2%.

Participants taking orforglipron also recorded substantial reductions in body weight. The estimated treatment difference for weight reduction was -8.9% in favor of orforglipron over the two-year period. In contrast, insulin glargine therapy did not produce comparable weight loss.

Gastrointestinal Side Effects and Study Dropouts

Adverse events in the digestive tract occurred more frequently in participants assigned to orforglipron. These gastrointestinal symptoms led to higher treatment discontinuation rates in the orforglipron group than in the insulin glargine group. The trial report did not specify the exact proportion of dropouts linked to specific digestive symptoms.

Insulin glargine maintains a steady baseline level of insulin for approximately 24 hours. Clinicians commonly introduce it when other blood sugar medications fail to maintain target glucose levels. Because insulin therapy carries well-documented risks of weight gain, an oral option that promotes weight loss presents a distinct clinical profile.

Tolerability remains a primary factor in whether patients can stay on daily nonpeptide GLP-1 therapy. The open-label trial design allowed participants and clinicians to know which treatment was administered, which can influence reporting of milder side effects.

Clinical Context for Diabetes Management

The trial results indicate that oral orforglipron could serve as an alternative to daily insulin injections for select patients with type 2 diabetes and high cardiovascular risk. People managing advanced type 2 diabetes who struggle with injection adherence or weight gain may benefit from discussing this evidence with their clinician.

This trial does not apply to individuals with type 1 diabetes, who require absolute insulin replacement. Patients should talk to their clinician about how nonpeptide GLP-1 receptor agonists compare with their current diabetes regimen. Any medication changes must balance cardiovascular safety, gastrointestinal tolerance, and individual metabolic targets.